VYNE Therapeutics receives FDA approval for trial of VYN202 [Yahoo! Finance]
VYNE Therapeutics Inc. (VYNE)
Company Research
Source: Yahoo! Finance
The double-blind, placebo-controlled, first-in-human trial will assess VYN202's safety, pharmacokinetics, pharmacodynamics and efficacy in both single ascending-dose (SAD) and multiple ascending-dose (MAD) portions. VYN202 is a selective bromodomain and extra-terminal domain (BET) inhibitor designed for treating immuno-inflammatory conditions. Around 64 healthy adult participants will be enrolled across five SAD and three MAD cohorts in the study. If the Phase Ia segment is successful, VYNE will advance the drug to Phase Ib trials in individuals suffering from moderate-to-severe plaque psoriasis and moderate-to-severe adult-onset rheumatoid arthritis. The company expects to report top-line results from the SAD/MAD trial in the second half of this year, with further results expected in the second half of next year. VYN202 is an oral small molecule designed for high selectivity (BD2 vs BD1), potent BD2 inhibition and optimal oral bioavailability. VYNE believes that by focus
Show less
Read more
Impact Snapshot
Event Time:
VYNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VYNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VYNE alerts
High impacting VYNE Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
VYNE
News
- VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- VYNE Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- VYNE Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.MarketBeat
- VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor [Yahoo! Finance]Yahoo! Finance
VYNE
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 4/3/24 - Form 4
- VYNE's page on the SEC website